BT2
BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC) [1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2].
Product Specifications
CAS Number
34576-94-8
Product Name Alternative
BAY1163877
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-Kinase/protease
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/bt2.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(O)C1=C(C2=CC=C(C=C2S1)Cl)Cl
Molecular Formula
C9H4Cl2O2S
Molecular Weight
247.10
Precautions
H315, H319, H335
References & Citations
[1]Tso SC, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. J Biol Chem. 2014 Jul 25;289 (30) :20583-93.|[2]Friberg A, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56 (1) :15-30.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Mcl-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
D9000-23N 100 µg
DRD5 (D (1B) Dopamine Receptor, D (5) Dopamine Receptor, D1beta Dopamine Receptor, Dopamine D5 Receptor, DRD1B, DRD1L2)
Sign In for Pricing
View Details 
